Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting 2024-12-09 08:20
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK 2024-10-31 13:00
CStone Reports 2024 Interim Results and Recent Corporate Updates 2024-08-23 22:20
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer 2024-07-26 20:16
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC 2024-06-02 08:24
CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website 2024-05-24 13:00
CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates 2024-03-27 22:00
CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer 2024-03-15 12:10
CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore 2023-12-21 17:10
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma 2023-12-08 12:10
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China 2023-11-01 18:10
CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication 2023-10-31 10:16
CStone Pharmaceuticals Reports 2023 Interim Results and Updates 2023-08-15 22:33
CStone announces GAVRETO® (pralsetinib) sNDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer 2023-06-27 08:05
CStone Pharmaceuticals Reports 2022 Annual Results and Business Updates 2023-03-15 22:13
CStone announces China's NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma 2023-02-28 08:05
CStone announces the registrational clinical trial of sugemalimab as first-line treatment in patients with esophageal squamous cell carcinoma met primary endpoints and plans to submit a supplemental NDA to NMPA 2023-01-03 08:10
CStone announces China's NMPA has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) 2022-09-13 08:02
CStone Pharmaceuticals Reports 2022 Interim Results and Business Updates 2022-08-25 18:00
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022 2022-08-08 08:08
1 2 3 4 5 7